Inmed Pharmaceuticals Inc SEC Filings

InMed Pharmaceuticals (INM) reported Q1 FY2026 results with Commercial segment sales of $1,120,121 versus $1,264,638 a year ago, reflecting lower pricing amid competition. Gross profit was $403,159 and the company recorded a net loss of $1,726,899 (basic and diluted EPS $(0.44)), compared with a net loss of $1,677,868 last year. Research and development expenses in the Pharma segment fell 17% to $575,458, while Commercial general and administrative costs rose 59% to $292,957.

Liquidity and balance sheet: Cash, cash equivalents and short‑term investments were $9,373,936 as of September 30, 2025, with cash and cash equivalents at $9,331,077. Total assets were $13,361,085, liabilities $1,770,462, and shareholders’ equity $11,590,623. Management states these resources are expected to fund operations into the fourth quarter of calendar 2026, yet concludes there is “substantial doubt” about continuing as a going concern. The quarter included the exercise of 602,000 pre-funded warrants, with an additional 200,000 exercised after quarter-end. Shares outstanding were 2,804,186 as of October 31, 2025.

InMed Pharmaceuticals (INM) announced its annual general and special meeting will be held virtually by telephone on December 17, 2025 at 4:00 p.m. Pacific. The meeting uses notice-and-access, with materials available online. The record date is October 22, 2025.

Shareholders will receive the audited financial statements (no vote), vote on the election of five directors (the Board size reduces as Bryan Baldasare will not stand for re‑election), and consider additional proposals including ratification of the independent auditor. A quorum requires two persons holding not less than 33⅓% of voting shares. 2,804,186 Common Shares were outstanding as of October 22, 2025. The Board reports that all directors other than the CEO are independent, maintains separate Chair and CEO roles, and outlines committee structures and attendance. The circular also details director fees effective October 1, 2024 and summarizes executive compensation, stock option practices, and change-in-control provisions.

InMed Pharmaceuticals (INM) filed a preliminary proxy for its annual general and special meeting, to be held virtually by telephone on December 17, 2025 at 4:00 p.m. PST. The record date is October 22, 2025, when 2,804,186 Common Shares were issued and outstanding.

Shareholders will receive the FY2025 audited financial statements (no vote), elect five directors (the Board is nominating five; one incumbent will not stand for re‑election), and vote on additional items including the ratification of CBIZ CPAs P.C. as auditor. Directors are elected by plurality; other proposals require a simple majority of votes cast. Auditor ratification is routine; the director election is non‑routine, so broker non‑votes will not count toward director elections. Quorum requires two persons holding not less than 33⅓% of the voting shares.

The Board reports that all directors other than the CEO are independent and maintains Audit, Compensation, and Governance/Nomination committees. As of the record date, Sabby Volatility Warrant Master Fund, Ltd. beneficially owned 280,138 shares (9.99%).

InMed Pharmaceuticals (INM) filed Amendment No. 1 to its Annual Report to amend and restate Part III—Items 10–14. The update replaces director and executive biographies, compensation, beneficial ownership, related-party transactions, director independence, and auditor fee disclosures, and removes the prior reference to incorporation by reference from a proxy. Other disclosures remain unchanged.

The company reports 2,384,186 common shares outstanding as of September 17, 2025 and an aggregate market value of non‑affiliates of $3,316,582 as of December 31, 2024. FY2025 audit fees were $212,000 (total fees $229,000) with CBIZ CPAs P.C. following its acquisition of Marcum LLP’s attest business on November 1, 2024. The Board’s committees (Audit, Compensation, Governance/Nomination) are composed of independent directors; the company maintains insider trading, anti‑hedging, and clawback policies. FY2025 CEO total compensation was $396,973. A beneficial ownership table as of October 22, 2025 lists Sabby Volatility Warrant Master Fund at 280,138 shares (9.99%), subject to stated beneficial ownership limits.

InMed Pharmaceuticals (INM) reported an initial statement of beneficial ownership by a director. The filing lists an employee stock option to purchase 3,500 common shares at an exercise price of $2.1, with an expiration date of 10/16/2030.

The event date is 10/14/2025. According to the vesting terms, the options were granted on 10/17/2025 and will vest monthly, in arrears: 98 options on the 17th of each month for 35 months, and 70 options on 10/17/2025. Ownership is reported as Direct.

InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025. The options expire on Oct 16, 2030.

Vesting is monthly in arrears: 98 options will vest on the 17th of each month for 35 months, and 70 options will vest on Oct 17, 2025, as described in the filing. Following the grant, the reporting person holds 3,500 derivative securities directly.

InMed Pharmaceuticals (INM) disclosed an initial beneficial ownership filing. A director submitted a Form 3 indicating their status as a Director and reporting no securities beneficially owned as of the event date 10/09/2024.

The Form 3 was filed by one reporting person and lists no direct or indirect holdings in either non-derivative or derivative securities. The filing is signed "/s/ Neil Klompas" and dated 10/17/2025.

InMed Pharmaceuticals appointed John Bathery to its Board, effective October 14, 2025, and increased the Board size to six members. His term runs until immediately before the company’s 2025 Annual General Meeting. Compensation follows the standard non-employee director program, including an annual retainer of US50,000; he also signed the company’s standard indemnification agreement.

Bryan Baldasare notified the company on October 15, 2025 that he will not stand for re-election at the 2025 Annual General Meeting, citing increasing professional obligations. The company stated there is no disagreement with Mr. Baldasare on matters of operations, policies, or practices.

InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.